Investigating response to PARP inhibition and androgen receptor pathway inhibition in C4-2B prostate cancer cells
RNA-seq (gene expression) · human · 39 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Prostate cancerThis series is part of our curated briefing on it.
- Samples
- 39 samples: 39 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate CancerBiomedicines · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE322615_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1430717 and SRA study SRP680303. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 39 sample titles: 39 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9555702 C4-2B Ola 0-1 1-day
- GSM9555703 C4-2B Ola 0-2 1-day
- GSM9555704 C4-2B Ola 0-3 1-day
- GSM9555705 C4-2B Ola 1-1 1-day
- GSM9555706 C4-2B Ola 1-2 1-day
- GSM9555707 C4-2B Ola 1-3 1-day
- GSM9555708 C4-2B Ola 5-1 1-day
- GSM9555709 C4-2B Ola 5-2 1-day
- GSM9555710 C4-2B Ola 5-3 1-day
- GSM9555711 C4-2B Ola 0-1 5-day
- GSM9555712 C4-2B Ola 0-2 5-day
- GSM9555713 C4-2B Ola 0-3 5-day
- GSM9555714 C4-2B Ola 1-1 5-day
- GSM9555715 C4-2B Ola 1-2 5-day
- GSM9555716 C4-2B Ola 1-3 5-day
- GSM9555717 C4-2B Ola 5-1 5-day
- GSM9555718 C4-2B Ola 5-2 5-day
- GSM9555719 C4-2B Ola 5-3 5-day
- GSM9555720 C42B DMSO A
- GSM9555721 C42B DMSO B
- GSM9555722 C42B DMSO C
- GSM9555723 C42B Abi 5 A
- GSM9555724 C42B Abi 5 B
- GSM9555725 C42B Abi 5 C
- GSM9555726 C42B Enz 20 A
- GSM9555727 C42B Enz 20 B
- GSM9555728 C42B Enz 20 C
- GSM9555729 C42B Ola 1 A
- GSM9555730 C42B Ola 1 B
- GSM9555731 C42B Ola 1 C
- GSM9555732 C42B Tala 10 A
- GSM9555733 C42B Tala 10 B
- GSM9555734 C42B Tala 10 C
- GSM9555735 C42B Abi 5 + Ola 1 A
- GSM9555736 C42B Abi 5 + Ola 1 B
- GSM9555737 C42B Abi 5 + Ola 1 C
- GSM9555738 C42B Enz 20 + Tala 10 A
- GSM9555739 C42B Enz 20 + Tala 10 B
- GSM9555740 C42B Enz 20 + Tala 10 C
- GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing · shares prostate
- GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing · shares prostate
- GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing · shares prostate
- GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing · shares prostate
- GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
- GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
- GSE245969 EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells 122 samples shares inhibition, receptor, prostate
- GSE288570 Tumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP-inhibition. 18 samples shares parp, inhibition
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.